NASDAQ: NBPNovabridge Biosciences Stock
$4.27-0.46 (-9.73%)
Updated Nov 4, 2025
NBP Price
$4.27
Fair Value Price
$0.26
Market Cap
$349.40M
52 Week Low
$0.60
52 Week High
$6.79
P/E
-8.84x
P/B
1.78x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$38.21M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.05
Operating Cash Flow
N/A
Beta
1.3
Next Earnings
Nov 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A
NBP Overview
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NBP's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NBP
Ranked#72 of 490
Ranked#72 of 490
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.27 | A | |
| $7.69 | A | |
| $102.92 | A |
Be the first to know about important NBP news, forecast changes, insider trades & much more!
NBP News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NBP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NBP ($4.27) is overvalued by 1,565.38% relative to our estimate of its Fair Value price of $0.26 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NBP ($4.27) is not significantly undervalued (1,565.38%) relative to our estimate of its Fair Value price of $0.26 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NBP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NBP due diligence checks available for Premium users.
Valuation
NBP fair value
Fair Value of NBP stock based on Discounted Cash Flow (DCF)
Price
$4.27
Fair Value
$0.26
Overvalued by
1,565.38%
NBP ($4.27) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NBP ($4.27) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NBP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NBP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-8.84x
Industry
-15.59x
Market
40.32x
NBP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.78x
Industry
4.87x
NBP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NBP's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.5M
Profit Margin
0%
Assets to liabilities
Assets
$206.7M
Liabilities
$10.0M
Debt to equity
0.05
NBP's short-term assets ($167.64M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NBP's short-term assets ($167.64M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NBP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NBP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
NBP vs Biotech Stocks
Novabridge Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.